Eisai Co., Ltd.

Stocks

4523

JP3160400002

Delayed Japan Exchange Other stock markets 06:07:19 15/07/2026 am IST			5-day change	1st Jan Change
4,291.00 ^JPY	-1.94%		-0.65%	-7.94%

15/07	Bioarctic AB Partner Eisai Presents Real-World Leader Study Results for Leqembi in Early Alzheimer?S Disease	CI
14/07	Eisai Co., Ltd. and Biogen Inc. Present Real-World LEADER Study Results For LEQEMBI At AAIC 2026	CI

Transcript : Eisai Co., Ltd. - Analyst/Investor Day

Published on 05/25/2026 at 04:06 pm IST - Modified on 05/25/2026 at 08:08 pm IST

S&P Capital IQ

Add MarketScreener to your sources

Presentation Operator Message
Operator (Operator)

It is now time. We would like to begin Investor Day corporate strategy. This is held in hybrid format, including in-person attendance and virtual

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Add MarketScreener to your sources

Latest news about Eisai Co., Ltd.

15/07	Bioarctic AB Partner Eisai Presents Real-World Leader Study Results for Leqembi in Early Alzheimer?S Disease	CI
14/07	Eisai Co., Ltd. and Biogen Inc. Present Real-World LEADER Study Results For LEQEMBI At AAIC 2026	CI
14/07	Biogen's Alzheimer's drug lowers toxic protein, but results were mixed	RE
14/07	FDA Approves Eisai, Biogen's LEQEMBI Injection for Early Alzheimer's	MT
14/07	Eisai Co., Ltd. And Biogen Inc. Receive FDA Approval For LEQEMBI IQLIK Subcutaneous Injection As Initiation Dose For Early Alzheimer?s Disease	CI
14/07	Eisai, Biogen Get FDA Approval for Treatment for Early Alzheimer's Disease	DJ
14/07	FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug	RE
13/07	Eisai Co., Ltd. Presents Latest Findings On Etalanetug Showing Reduction In Alzheimer's Disease Tau Tangle-Specific Plasma Biomarker MTBR-Tau243 at Alzheimer's Association International Conference 2026	CI
12/07	Eisai Co., Ltd. And Biogen Inc. Present Clinical Data Supporting Leqembi Subcutaneous Autoinjector Efficacy And Safety Comparable To Intravenous Formulation In Early Alzheimer's Disease	CI
02/07	Eisai Co., Ltd.'s Acceptance of Marketing Authorization Application for In-house Developed Insomnia Drug Lemborexant for Evaluation by the United Kingdom?s Medicines and Healthcare Products Regulatory Agency	CI
30/06	Eisai Present New Clinical And Real-World Evidence On Lecanemab At AAIC Conference	CI
30/06	Eisai Co Ltd Showcases Alzheimer?s Disease Portfolio With Over 50 Presentations At Alzheimer?s Association International Conference 2026	CI
30/06	University College London And Eisai Co., Ltd. Renew Partnership To Accelerate Treatments For Neurodegenerative Diseases	CI
29/06	Nuvation Bio Validates Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced Ros1-Positive Non-Small Cell Lung Cancer in the United Kingdom	CI
16/06	Eisai to Invest GBP 48 Million in UK Site for Cold-Chain Drug Capabilities	MT